We are a privately held biotechnology company that has developed a diagnostic platform allowing for disease management and diagnosis through prognosis, all from a simple blood test. The Biofluidica diagnostic platform is able to precisely capture and isolate disease biomarkers, such as Circulating Tumor Cells, CTC’s, and has been clinically validated. Our ability to scan blood for the first signs of a disease, finding the rarest biomarkers with unmatched sensitivity, means fulfilling the promise of a true liquid biopsy. We are revolutionizing disease diagnostics by bringing better diagnostics to millions of people.